SKP2 (human)

LTP

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

HTP

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

S34-gl

SKTSELLsGMGVSAL

Upstream

Downstream

Effects on Modified Protein

enzymatic activity, induced
molecular association, regulation
protein stabilization
ubiquitination

Effects on Biological Processes:

carcinogenesis, induced
cell cycle regulation
cell growth, induced

Treatment

siRNA
thiamet-G

SKP2 (human)	SKTSELLsGMGVSAL	S34-gl
SKP2 (mouse)	SKTSELLSGMGVSAL	S34

K43-sm

MGVSALEkEEPDsEN

SKP2 (human)	MGVSALEkEEPDsEN	K43-sm
SKP2 (mouse)	MGVSALEKEEVDSEN	K43

S48-p

LEkEEPDsENIPQEL

SKP2 (human)	LEkEEPDsENIPQEL	S48-p
SKP2 (mouse)	LEKEEVDSENIPHGL	S48

S57-p

NIPQELLsNLGHPEs

SKP2 (human)	NIPQELLsNLGHPEs	S57-p
SKP2 (mouse)	NIPHGLLSNLGHPQs	S57

S64-p

sNLGHPEsPPRkRLk

Upstream

Downstream

SKP2 (human)
S64-p

14865 : Phospho-Skp2 (Ser64) Antibody

Effects on Modified Protein

activity, induced
molecular association, regulation
phosphorylation
protein stabilization
ubiquitination

Effects on Biological Processes:

carcinogenesis, induced
cell cycle regulation
cell growth, induced
transcription, induced

Kinase, in vitro:

CDK2 (human)
Pim1 (rat)

Phosphatases, in vitro:

CDC14B (human)

Putative in vivo kinases:

CDK2 (human)
P38A (human)
Pim1 (human)

Putative upstream phosphatases:

CDC14B (human)

Regulatory protein:

CCNA2 (human)
CCNB1 (human)
CCNE1 (human)

Treatment

coculture
nocodazole
olomoucine
seliciclib
siRNA
SMI-4a
SU9516
wortmannin

SKP2 (human)	sNLGHPEsPPRkRLk	S64-p
SKP2 (mouse)	SNLGHPQsPPRkRVk	S64-p

K68-ac

HPEsPPRkRLkskGs

Upstream

Downstream

Effects on Modified Protein

intracellular localization
protein stabilization

Effects on Biological Processes:

carcinogenesis, induced
cell motility, induced

Regulatory protein:

CBP (human)
GCN5 (human)
SIRT4 (human)

Treatment

garcinol
insulin
siRNA

SKP2 (human)	HPEsPPRkRLkskGs	K68-ac
SKP2 (mouse)	HPQsPPRkRVkGKGS	K68-ac

K71-ac

sPPRkRLkskGsDkD

Upstream

Downstream

Effects on Modified Protein

intracellular localization
protein stabilization

Effects on Biological Processes:

carcinogenesis, induced
cell motility, induced

Regulatory protein:

CBP (human)
GCN5 (human)
SIRT4 (human)

Treatment

garcinol
insulin
siRNA

SKP2 (human)	sPPRkRLkskGsDkD	K71-ac
SKP2 (mouse)	sPPRkRVkGKGSDKD	K71-ac

S72-p

PPRkRLkskGsDkDF

Upstream

Downstream

Effects on Modified Protein

activity, induced
phosphorylation
protein stabilization

Effects on Biological Processes:

cell cycle regulation

Kinase, in vitro:

Pim1 (rat)

Putative in vivo kinases:

Akt1 (human)
Pim1 (human)

Treatment

insulin
seliciclib
SMI-4a
tautomycin
wortmannin

SKP2 (human)	PPRkRLkskGsDkDF	S72-p
SKP2 (mouse)	PPRkRVkGKGSDKDF	G72

K73-ub

PRkRLkskGsDkDFV

SKP2 (human)	PRkRLkskGsDkDFV	K73-ub
SKP2 (mouse)	PRkRVkGKGSDKDFV	K73

S75-p

kRLkskGsDkDFVIV

SKP2 (human)	kRLkskGsDkDFVIV	S75-p
SKP2 (mouse)	kRVkGKGSDKDFVII	S75

K77-ub

LkskGsDkDFVIVRR

SKP2 (human)	LkskGsDkDFVIVRR	K77-ub
SKP2 (mouse)	VkGKGSDKDFVIIRR	K77

K125-ub

LKVSGVCkRWYRLAS

SKP2 (human)	LKVSGVCkRWYRLAS	K125-ub
SKP2 (mouse)	LRVSGVCKRWYRLSL	K125

K145-ub

QTLDLTGkNLHPDVT

SKP2 (human)	QTLDLTGkNLHPDVT	K145-ub
SKP2 (mouse)	QSLDLAGKNLHPDVT	K145

S179-p

QPLAEHFsPFRVQHM

SKP2 (human)	QPLAEHFsPFRVQHM	S179-p
SKP2 (mouse)	QPLGESFSSFRVQHM	S179

S212-p

CSKLQNLsLEGLRLS

SKP2 (human)	CSKLQNLsLEGLRLS	S212-p
SKP2 (mouse)	CSKLQNLSLEGLQLS	S212

N224

RLSDPIVNTLAkNSN

SKP2 (human)	RLSDPIVNTLAkNSN	N224
SKP2 (mouse)	QLSDPIVkTLAQNEN	K224-ub

K228-ub

PIVNTLAkNSNLVRL

SKP2 (human)	PIVNTLAkNSNLVRL	K228-ub
SKP2 (mouse)	PIVkTLAQNENLVRL	Q228

S256-p

QTLLSSCsRLDELNL

Upstream

Downstream

Effects on Modified Protein

enzymatic activity, induced
molecular association, regulation
phosphorylation
ubiquitination

Effects on Biological Processes:

carcinogenesis, induced
cell growth, induced
cell motility, induced
signaling pathway regulation
transcription, induced

Kinase, in vitro:

AMPKA1 (human)
AMPKB1 (human)
AMPKG2 (human)

Putative in vivo kinases:

AMPKA1 (human)

Treatment

compound_C
EGF
glucose_starvation
H2O2
hypoxia
siRNA

SKP2 (human)	QTLLSSCsRLDELNL	S256-p
SKP2 (mouse)	ATLLSSCsRLDELNL	S256-p

K299-ub

GYRKNLQkSDLsTLV

SKP2 (human)	GYRKNLQkSDLsTLV	K299-ub
SKP2 (mouse)	GYRKNLQKTDLCTII	K299

S303-p

NLQkSDLsTLVRRCP

SKP2 (human)	NLQkSDLsTLVRRCP	S303-p
SKP2 (mouse)	NLQKTDLCTIIKRCP	C303

K405-ub

RPTIGNKkNQEIWGI

SKP2 (human)	RPTIGNKkNQEIWGI	K405-ub
SKP2 (mouse)	RPTMDSKKNLEIWGI	K405

K413-ub

NQEIWGIkCRLtLQk

SKP2 (human)	NQEIWGIkCRLtLQk	K413-ub
SKP2 (mouse)	NLEIWGIKCRLTLQK	K413

T417-p

WGIkCRLtLQkPSCL

Upstream

Downstream

Effects on Modified Protein

activity, induced
protein stabilization
ubiquitination

Effects on Biological Processes:

cell cycle regulation

Kinase, in vitro:

Pim1 (rat)

Putative in vivo kinases:

Pim1 (human)

Treatment

seliciclib
SMI-4a
wortmannin

SKP2 (human)	WGIkCRLtLQkPSCL	T417-p
SKP2 (mouse)	WGIKCRLTLQKPSCL	T417

K420-ub

kCRLtLQkPSCL___

SKP2 (human)	kCRLtLQkPSCL___	K420-ub
SKP2 (mouse)	KCRLTLQKPSCL___	K420